Humana Inc. reported a staggering fourth-quarter loss of $1.01 billion, pushing its stock down 29% despite a year-over-year revenue increase of 11.4% to $32.52 billion. The company's declining Medicare Star Ratings pose a risk to future quality bonus payments, contributing to projections of decreased earnings for 2026. Amid these challenges, Humana is seeking to recover margins through strategic investments and will host a live Q&A session to address concerns regarding its financial outlook.
“Humana · is headquartered in · Louisville, Kentucky”
“Humana · is a leading healthcare company that offers · a wide range of products”
“Humana · provides · Medicare Advantage coverage · nearly 5.2 million members”
“Humana · was raised · to Buy from Hold at Deutsche Bank · with a $441 target price”
“Humana Inc. · is well poised for growth · benefiting from increasing premiums, strategic acquisitions, an expanding value-based care platform, an aging population in the United States and solid cash generation capacity · true”
“HUM · has gained · 23.7% · over the past year”
“HUM · offers health insurance benefits through · Health Maintenance Organization, Private Fee-For-Service and Preferred Provider Organization plans · true”
“HUM · provides specialty products such as · dental, vision and other supplementary benefits · true”
“HUM · currently carries a Zacks Rank · #3 (Hold) · true”
“The Zacks Consensus Estimate for Humana’s 2026 earnings · is pegged at · $9.02 per share · true”
“HUM · witnessed one upward estimate revision and one in the opposite direction · in the past seven days · true”
“The consensus mark for revenues · is pegged at · $162.6 billion for 2026 · true”